Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Christopher Strouse, Carla Casulo, Eric Mou, Melissa C. Larson, Brianna Gysbers, Allison C. Rosenthal, Andrew L. Feldman, Matthew J. Maurer, Kathleen Yost, Susan L. Slager, Brian K. Link, Thomas M. Habermann, Amylou Constance Dueck, James R. Cerhan

Blood (2023) 142 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2023-186862

Published: 2023

Journal Articles

Autologous Stem Cell Transplant in Fit Patients with Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy

Aung M. Tun, Seth Maliske, Yucai Wang, David James Inwards, Thomas M. Habermann, Ivana Micallef, Luis Porrata, Jonas Paludo, J. C. Villasboas, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Stephen M Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B Johnston

Blood (2023) 142 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2023-185002

Published: 2023

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Prior to CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2127.

https://doi.org/10.1182/blood-2023-186806

Published: 2023

Journal Articles

Treatment Pattern and Survival Outcome of Limited Stage Mantle Cell Lymphoma: A National Cancer Database Analysis in Pre-BTK Inhibitor Vs BTK Inhibitor Era

Jihao Zhou, Jacqueline F. Wang, Steven Ray Hwang, Jonas Paludo, Javier L. Munoz, David James Inwards, Allison C. Rosenthal, William Breen, Scott Lester, Stephen M Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2023-177790

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

Christian Grommes, Grzegorz S. Nowakowski, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Meaghan Fowle, Maureen Lane, Catherine Wang, Antonio Omuro, Lori A. Leslie, Carole Soussain, Anna Paulina Dabrowska-Iwanicka, Andrés José María Ferreri, Han Tun

Blood (2023) 142 (Supplement 1): 3143.

https://doi.org/10.1182/blood-2023-190391

Published: 2023

Journal Articles

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2023-188155

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

Journal Articles

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Christian Grommes, Han Tun, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Wanying Zhao, Maureen Lane, Catherine Wang, Reinhard von Roemeling, Iris Isufi, Lori A. Leslie, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2023-189746

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study

Aung M. Tun, Romil Patel, Frederique St-Pierre, Evguenia Ouchveridze, Alex Niu, Jennifer Obasi, Allison C. Rosenthal, Priyanka A Pophali, Timothy S. Fenske, Reem Karmali, Sairah Ahmed, Patrick B Johnston

Blood (2023) 142 (Supplement 1): 311.

https://doi.org/10.1182/blood-2023-179509

Published: 2023

Journal Articles

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Sowjanya Vuyyala, Andre De Menezes Silva Corraes, Megumi Bailey, Madiha Iqbal, Javier L. Munoz, Bradley Hunter, Radhika Bansal, Krish Patel, Mohamed A. Kharfan-Dabaja, Allison C. Rosenthal, Yucai Wang, Jonas Paludo, Patrick B Johnston, N. Nora Bennani, J. C. C. Villasboas, Urshila Durani, Stephen M Ansell, Yi Lin, Arushi Khurana

Blood (2023) 142 (Supplement 1): 6926.

https://doi.org/10.1182/blood-2023-188441

Published: 2023

Journal Articles

Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis

Charles Gaulin, Matthew Ulrickson, Muhammad Husnain, Madiha Iqbal, Paschalis Vergidis, Allison C. Rosenthal, Hemant S. Murthy, Carolyn Mead-Harvey, Yucai Wang, Januario E. Castro, Jeanne M. Palmer, Jose F. Leis, Patrick B. Johnston, Janis E. Blair, Mohamed A. Kharfan-Dabaja, Yi Lin, Javier Munoz

Blood (2022) 140 (Supplement 1): 12111–12113.

https://doi.org/10.1182/blood-2022-159744

Published: 2022

Journal Articles

Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

George W. Wright, Colleen A. Ramsower, James R. Cerhan, Anne J. Novak, Brian K. Link, Matthew J. Maurer, Raphael Mwangi, Allison C. Rosenthal, Thomas M. Habermann, Lou Staudt, Robert Kridel, David W. Scott, Christian Steidl, Lisa M. Rimsza

Blood (2022) 140 (Supplement 1): 6426–6427.

https://doi.org/10.1182/blood-2022-160351

Published: 2022

Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10396–10398.

https://doi.org/10.1182/blood-2022-169689

Published: 2022

Journal Articles

Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy

Blood (2021) 138 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2021-146119

Published: 2021

Journal Articles

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Allison C. Rosenthal, Colleen Ramsower, Raphael Mwangi, Matthew J. Maurer, Diego Villa, Timothy J. McDonnell, Andrew L. Feldman, Thomas M. Habermann, Jonathon B. Cohen, Ryan S. Robetorye, Elías Campo, Eva Giné, James R. Cook, Brian T. Hill, Philipp Raess, German Ott, Alexander Reichart, David W. Scott, Lisa M. Rimsza

Blood (2021) 138 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2021-151275

Published: 2021

Journal Articles

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali Kamdar, Brian T. Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid W Merryman, Paolo Strati

Blood (2021) 138 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2021-147591

Published: 2021

Journal Articles

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination

Michael T. Francisco, Adrienne E. Kaufman, Donald Northfelt, Leslie Padrnos, Allison C. Rosenthal, Jennifer Andres, Jill Adamski, Theresa Kinard, John Camoriano

Blood (2021) 138 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2021-151964

Published: 2021

Journal Articles

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2021-151859

Published: 2021

NARROW

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Autologous Stem Cell Transplant in Fit Patients with Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Prior to CAR T-Cell Therapy

Treatment Pattern and Survival Outcome of Limited Stage Mantle Cell Lymphoma: A National Cancer Database Analysis in Pre-BTK Inhibitor Vs BTK Inhibitor Era

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma

The Impact of Pre-Existing Autoimmune Disease on the Safety and Efficacy of CAR T-Cell Therapy for Non-Hodgkin Lymphoma

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Chimeric Antigen Receptor T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multicenter Study

Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis

Low Incidence of Fungal Infections after Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma in an Endemic Region for Coccidioidomycosis

Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only